While many utilize the 30 Gy in 5 once-daily fractions regimen for APBI, there is still debate over the optimal APBI dose. Here is long-term follow up from a 15 year old APBI dose escalation trial. It included 324 patients with low or intermediate grade DCIS or stage I invasive breast cancer. They were treated with 4 Gy per fraction delivered twice daily to a total of 32 Gy, 36 Gy, or 40 Gy. At 15 years, the cumulative incidence of local failure was 6.9% after 32 Gy, 5% after 36 Gy, and 3.9% after 40 Gy. While this looks numerically different based on dose, the differences did not reach statistical significance (P=.21). What did reach significance were higher rates of severe fibrosis (40% v 58% v 67%) and more patient-rated fair or poor cosmesis (25% v 30% v 49%). | Taghian, Int J Radiat Oncol Biol Phys 2024

